Advances in Neurovascular Stenting for Stroke Prevention
Stroke remains a leading cause of long-term disability and mortality worldwide. While medical management and acute interventions like thrombectomy have significantly improved outcomes, the role of neurovascular stenting in both acute and preventive settings continues to evolve. Recent clinical trials and technological advancements are reshaping treatment paradigms, offering new hope for patients at risk of or experiencing stroke [1] [2].
The Evolving Landscape of Intracranial Stenting
Intracranial atherosclerotic disease (ICAD), characterized by plaque buildup in the brain's arteries, is a significant contributor to ischemic stroke. Historically, treatment for symptomatic ICAD primarily involved aggressive medical management. However, recent studies have demonstrated the efficacy of intracranial stenting in select patient populations. The **BASIS (Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis) trial**, a randomized clinical trial involving 501 patients, revealed that submaximal balloon angioplasty combined with aggressive medical management significantly reduced the risk of stroke or death within 30 days, or ischemic stroke/revascularization within 12 months, compared to medical management alone [1]. This suggests a crucial role for interventional approaches when medical therapy proves insufficient.
Conversely, the **ANGEL-REBOOT trial** explored bailout angioplasty or stenting in acute large vessel occlusion ischemic stroke patients who had unsuccessful recanalization after thrombectomy. This study found that such bailout procedures did not improve functional outcomes at 90 days and were associated with a higher risk of complications, including symptomatic intracranial hemorrhage [1]. These contrasting results highlight the importance of patient selection and timing in neurovascular interventions.
Carotid Artery Stenting: A Proactive Approach
Beyond intracranial applications, carotid artery stenting (CAS) plays a vital role in preventing strokes caused by carotid stenosis—a narrowing of the carotid arteries in the neck. A landmark study, the **CREST-2 trial**, investigated the effectiveness of CAS and carotid endarterectomy (CEA) alongside intensive medical therapy in asymptomatic patients with severe carotid artery narrowing (70% or greater). The findings indicated that supplementing a stent to medical management significantly reduced the four-year risk of stroke by approximately half, from 6% for medical management alone to 2.8% [2]. This evidence strongly supports CAS as a proactive measure for stroke prevention in high-risk asymptomatic individuals.
Innovations in Stent Technology
The field of neurovascular stenting is continuously driven by technological innovation. Advances include the development of novel stent designs, such as braided and self-expanding stents, which offer improved navigability, vessel wall apposition, and reduced risk of complications. For instance, the **BosSTENT** by Sonorous Neurovascular, which recently received FDA breakthrough designation, represents a novel braided, self-expanding stent [3]. Furthermore, devices like the **LVIS EVO** from MicroVention (Terumo Neuro) provide enhanced visualization and optimized opening characteristics, facilitating more precise and safer procedures [4]. These technological strides aim to overcome the limitations of earlier-generation stents, improving both the safety and efficacy of neurovascular interventions.
Future Directions and Considerations
The ongoing evolution of neurovascular stenting necessitates continued research to refine patient selection criteria, optimize procedural techniques, and evaluate long-term outcomes. The integration of advanced imaging modalities, such as high-resolution intracranial vessel wall imaging, is crucial for accurate diagnosis and personalized treatment planning [5]. While neurovascular stenting offers significant benefits for stroke prevention and treatment, it is imperative that these procedures are performed by experienced neurovascular specialists within comprehensive stroke centers to ensure optimal patient care and outcomes. It is important to note that this information is for academic purposes and does not constitute medical advice.
References
[1] Mehta, A., Sheth, S., & Jadhav, A. P. (2025). Neurointerventional Advances in 2024. *Stroke: Vascular and Interventional Neurology*, 5(2). [https://www.ahajournals.org/doi/10.1161/SVIN.124.001685](https://www.ahajournals.org/doi/10.1161/SVIN.124.001685) [2] UAB News. (2025, November 21). *Stenting with medication cuts stroke risk in half for high-risk patients, UAB research shows*. [https://www.uab.edu/news/research-innovation/stenting-with-medication-cuts-stroke-risk-in-half-for-high-risk-patients-uab-research-shows](https://www.uab.edu/news/research-innovation/stenting-with-medication-cuts-stroke-risk-in-half-for-high-risk-patients-uab-research-shows) [3] MassDevice. (2026, February 6). *Sonorous Neurovascular earns FDA breakthrough mark for novel stent*. [https://www.massdevice.com/sonorous-neurovascular-earns-fda-breakthrough-mark-for-novel-stent/](https://www.massdevice.com/sonorous-neurovascular-earns-fda-breakthrough-mark-for-novel-stent/) [4] Terumo Neuro. (n.d.). *MicroVention Announces the Next Evolution in Stent Innovation*. [https://www.terumoneuro.com/newsroom/press-releases/microvention-announces-the-next-evolution-in-stent-innovation-microventions](https://www.terumoneuro.com/newsroom/press-releases/microvention-announces-the-next-evolution-in-stent-innovation-microventions) [5] Cedars-Sinai. (2023, November 15). *A Stent—And No Stroke—For This Patient*. [https://www.cedars-sinai.org/newsroom/a-stentand-no-strokefor-this-patient/](https://www.cedars-sinai.org/newsroom/a-stentand-no-strokefor-this-patient/)